Andrew J. Armstrong
YOU?
Author Swipe
View article: A memory-driven reinforcement learning model of phenotypic adaptation for anticipating therapeutic resistance in prostate cancer
A memory-driven reinforcement learning model of phenotypic adaptation for anticipating therapeutic resistance in prostate cancer Open
While contemporary cancer treatment strategies have significantly prolonged the lives of patients, therapeutic resistance remains a predominant cause of disease progression and cancerrelated deaths. Cancer therapy often induces gene regula…
View article: Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer Open
Results for ORR, DoR, confirmed PSA50-RR, and time to PSA progression favoured Ola + Abi over P + Abi in the ITT population and biomarker subgroups. The data support consideration of Ola + Abi as first-line treatment for mCRPC.
View article: DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis Open
These findings indicate that darolutamide offers effectiveness and a favorable safety profile in the broad range of patients seen in clinical practice.
View article: Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617
Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 Open
Background 177Lu-PSMA-617 is approved for patients with metastatic castration-resistant prostate cancer (mCRPC). Although treatment is associated with improved outcomes, not all patients benefit and response is heterogeneous. We aim to cha…
View article: Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels Open
View article: Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair–deficient Metastatic Castration-resistant Prostate Cancer
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair–deficient Metastatic Castration-resistant Prostate Cancer Open
These data confirm the efficacy of anti-PD-(L)1 therapy in patients with dMMR mCRPC and warrant consideration of reimbursement for anti-PD-(L)1 agents in dMMR mCRPC by health authorities.
View article: Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPC Open
Enzalutamide + ADT showed better efficacy than darolutamide + ADT for treatment of patients with mHSPC. These findings can help inform treatment decisions in clinical practice.
View article: SCORT–Cas13d Nanotherapy Precisely Targets the ‘Undruggable’ Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo
SCORT–Cas13d Nanotherapy Precisely Targets the ‘Undruggable’ Transcription Factor HoxB13 in Metastatic Prostate Cancer In Vivo Open
Metastatic cancer, the primary cause of cancer mortality, frequently exhibits heightened dependence on certain transcription factors (TFs), which serve as master regulators of oncogenic signaling yet are often untargetable by small molecul…
View article: Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer Open
Importance In men with metastatic hormone-sensitive prostate cancer (mHSPC), prostate-specific antigen (PSA) decline after treatment has been associated with improved survival. However, the data on PSA decline are limited in men with mHSPC…
View article: Figure S9 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S9 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S9. Serum PSA and disease category by CTC phenotype for all samples.
View article: Figure S11 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S11 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S11. Luminal B phenotype is associated with activation of pathways associated with RB1 and PTEN loss.
View article: Figure S12 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S12 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S12. Pretreatment CTC and PSMA-PET characteristics in the 177Lu-PSMA-617 sub-study cohort.
View article: Supplementary Genesets from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Supplementary Genesets from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Supplementary Genesets includes prostate cancer specific genesets curated from published literature
View article: Figure S1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S1. Calibration of ESTIMATE tumor content prediction.
View article: Figure 2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure 2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Gene expression of epithelial and prostate adenocarcinoma–associated genes across CTC phenotypes. A, Schematic of the CTC transcriptional phenotypes. B and C, Epithelial keratin (KRT8 and KRT18) gene expr…
View article: Figure S15 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S15 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S15. Longitudinal FOLH1 expression and pathway analysis of CTCs in the 177Lu-PSMA-617 sub-study cohort.
View article: Figure S3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S3. Reproducibility of tumor/immune content assessment, gene expression and pathway scores.
View article: Figure S14 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S14 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S14. Luminal B phenotype is associated with higher MYC signaling and lower radiation response scores.
View article: Figure 3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure 3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Luminal-B CTC phenotype is associated with poor prognosis and adverse clinical features. A, Serum PSA (ng/mL) at the time of CTC collection in the survival analysis subset (Low_CTC, n = 63; Low_prolif, n = 12; LumA,
View article: Figure S10 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S10 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S10. Sample cDNA concentration and tumor fraction by CTC phenotype in the survival analysis subset.
View article: Figure 6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure 6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Cell-surface target expression is variable across CTC phenotypes. A, Heatmap of gene expression of cell-surface targets ordered by clustering in Fig. 1D. B–J, Cell-surface target expression by CTC phenotype for targets associ…
View article: Table 1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Table 1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Clinical characteristics of cohort and CTC phenotype groups.
View article: Figure S2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S2. RNA sequencing quality metrics
View article: Figure S6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S6. Expression of epithelial and prostate adenocarcinoma genes across CTC phenotypes for all samples.
View article: Figure 5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure 5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Luminal-B CTC phenotype and persistent PSMA expression are associated with poor response to 177Lu–PSMA-617. A, Clinical benefit rate (the best radiographic response of stable disease, partial response, or complete respons…
View article: Figure S7 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S7 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S7. Expression of neuroendocrine genes across CTC phenotypes.
View article: Figure S16 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S16 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S16. Cell surface target expression across CTC phenotype clusters for all samples.
View article: Figure S17 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S17 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S17. Concordance between protein and RNA expression of cell surface targets in prostate CTCs.
View article: Figure S5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S5. Tumor fraction and immune content across CTC phenotypes.
View article: Table S1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Table S1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Table S1. Clinical characteristics of the 177LuPSMA-treated cohort